Kliniken Suedostbayern AG

Research site

Germany Cuno-Niggl-Strasse 3, 83278 Traunstein, Germany

12 trials recruiting
Acute myeloid leukaemia · Non-small cell lung cancer · Non-small cell lung cancer metastatic
Adult patients

About Specializations

Kliniken Suedostbayern AG in Traunstein, Germany specialises in clinical trials of conditions such as Acute myeloid leukaemia, Non-small cell lung cancer, Non-small cell lung cancer metastatic, Non-small cell lung cancer stage IV, and other specialisations. This site conducts important research.

Main research areas of the site

Hemic and Lymphatic Diseases

At Kliniken Suedostbayern AG the hematology‑oncology‑palliative care department concentrates on lymphoma research, with a particular focus on older adults who cannot tolerate full‑dose chemotherapy.

Combination therapy with a BTK inhibitor
Reduced‑dose chemotherapy strategies
Outcomes in patients over 80 years of age
Safety profiling in frail populations

Five investigators are leading efforts to improve progression‑free survival for patients with Diffuse large B‑cell lymphoma by testing a new drug‑plus‑chemo regimen.

Neoplasms

The site also addresses a broad spectrum of high‑grade B‑cell lymphomas, including rare variants such as primary mediastinal large B‑cell lymphoma and ALK‑positive large B‑cell lymphoma.

Molecular characterization of MYC/BCL2 rearranged lymphomas
Evaluation of novel targeted agents
Clinical assessment of lymphoma subtypes with viral association
Integration of diagnostic biomarkers

Through two active trials, the team aims to refine treatment options and expand therapeutic choices for patients with aggressive neoplasms across Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Cuno-Niggl-Strasse 383278 TraunsteinGermany

Open in maps ↗

Recruiting now: 12 trials
Conditions studied: 34

More sites in Traunstein Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

19 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Germany

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AGO Research GmbH

Contact Research Centre

Colon cancer stage III+1

Recruiting

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Acute lymphocytic leukaemia

Recruiting

Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Blinatumomab
Sponsor:Goethe University Frankfurt

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Celgene Corp.

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Double hit lymphoma+7

Recruiting

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Universitaet Des Saarlandes

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites